Related Experiment Video
Updated: Sep 16, 2025

A Melanoma Patient-Derived Xenograft Model
Published on: May 20, 2019
Characterization of Melanoma in Hungary Based on a Retrospective Single-Center Study Between 2001 and 2018
Renáta Gubán1,2,3, Petra Parrag2,3, Mihály Tamás Kispál1
1Department of Dermato-Oncology, National Institute of Oncology and National Tumor Laboratory, 1122 Budapest, Hungary.
None:
Background/Objectives: Over the past few decades, the incidence of melanoma has been steadily rising. In Hungary, the National Institute of Oncology serves as the national center for the diagnosis and treatment of malignancies, including melanoma. This study aims to analyze our patients' data, providing a comprehensive characterization of melanoma across the country. Methods: We systematically analyzed the clinico-pathological data of melanoma patients treated in the Department of Oncodermatology between 2001 and 2018. Prognostic parameters were collected from the Hospital Information System of the Institute, including gender, age, tumor location, exulceration of primary lesion, Clark level, and Breslow thickness. In addition, survival analysis was also performed. Results: A total of 6267 melanoma patients were included in the study, with a slight predominance of female cases. The most common tumor location was the trunk. Female patients and younger age groups were more likely to present with lower Breslow thickness, while tumors in the head region were associated with increased thickness. Over the study period, the annual median Breslow thickness showed a significant decline. Female gender, younger age, and lower Breslow thickness was correlated with improved overall survival. Over time, the studied patient population exhibited better outcomes. Conclusions: Despite the rising incidence of melanoma in Hungary, the annual median Breslow thickness in our studied patient group showed a decreasing trend, accompanied by improved mortality outcomes. This highlights the critical role of secondary prevention measures and their effectiveness, as well as the impact of novel therapeutic advancements.

